Clinical Trial Update: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports results for sacituzumab govitecan with or without pembrolizumab in HR-positive, HER2-negative metastatic breast cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Ana C Garrido-Castro, MD | Conditions: Invasive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-30